Sera Prognostics (NASDAQ:SERA – Get Free Report) is projected to release its earnings data before the market opens on Wednesday, March 19th. Analysts expect Sera Prognostics to post earnings of ($0.23) per share for the quarter.
Sera Prognostics Price Performance
Sera Prognostics stock opened at $4.22 on Wednesday. Sera Prognostics has a 12 month low of $3.84 and a 12 month high of $12.36. The stock has a market capitalization of $142.52 million, a PE ratio of -4.26 and a beta of 0.89. The business has a 50 day simple moving average of $5.54 and a 200-day simple moving average of $6.73.
Insider Buying and Selling
In other news, General Counsel Benjamin Jackson sold 13,272 shares of Sera Prognostics stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.42, for a total value of $98,478.24. Following the sale, the general counsel now owns 128,473 shares in the company, valued at $953,269.66. This trade represents a 9.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the sale, the director now directly owns 2 shares of the company’s stock, valued at $12.78. This represents a 99.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,877 shares of company stock valued at $480,677. 15.80% of the stock is owned by corporate insiders.
Sera Prognostics Company Profile
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
Recommended Stories
- Five stocks we like better than Sera Prognostics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What Investors Need to Know About Upcoming IPOs
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- How to Invest in the FAANG Stocks
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.